Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Previous EU Guidance Wrong On Format Rule For Mutual Recognition Procedures

Executive Summary

Contrary to previous guidance, applicants must submit as of Jan 1 all MRP submissions in eCTD format, including submissions for ongoing regulatory activities which may not have been originally submitted in this format.

You may also be interested in...



Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says

Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.

Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says

Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.

Canada Allows Exemptions To Mandatory eCTD Format In Justified Cases

Drug sponsors operating in Canada might be able to get an exemption from a new requirement that as of Jan. 1 required them to start filing certain regulatory activities in the electronic common technical document (eCTD) format

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel